Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Yunzhen Qian"'
Autor:
Yusheng Chen, Xuan Lin, Xuan Zou, Yunzhen Qian, Yu Liu, Ruijie Wang, Xu Wang, Xianjun Yu, Chen Liu, He Cheng
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-15 (2023)
Abstract Background Pancreatic adenocarcinoma (PAAD) remains a lethal malignancy making the detection of novel prognostic biomarkers urgent. Limited studies have investigated the predictive capability of immune checkpoints in PAAD. Method Gene expres
Externí odkaz:
https://doaj.org/article/f4c5b131b40148c5a7788a14c519bcad
Autor:
Yunzhen Qian, Yitao Gong, Guopei Luo, Yu Liu, Ruijie Wang, Xuan Zou, Shengming Deng, Xuan Lin, Yusheng Chen, Xu Wang, Xianjun Yu, He Cheng, Chen Liu
Publikováno v:
World Journal of Surgical Oncology, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background Intraductal papillary mucinous neoplasms (IPMNs) are characterized by their abundant mucin production and malignant potential. IPMNs of the pancreas are mainly managed according to their radiographic indications, but this approach
Externí odkaz:
https://doaj.org/article/d709b2166a8c442095c5d75c6a25d4fb
Autor:
Yunzhen Qian, Yitao Gong, Xuan Zou, Yu Liu, Yusheng Chen, Ruijie Wang, Zhengjie Dai, Yesiboli Tasiheng, Xuan Lin, Xu Wang, Guopei Luo, Xianjun Yu, He Cheng, Chen Liu
Publikováno v:
Oncogenesis, Vol 11, Iss 1, Pp 1-13 (2022)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a well-known lethal and heterogeneous disease. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) is an important mutagenic driver that has seldom been investigated in PDAC. Th
Externí odkaz:
https://doaj.org/article/e9c647b9cdbe41d09afcc64fcfe4e99c
Autor:
Yitao Gong, Yunzhen Qian, Guopei Luo, Yu Liu, Ruijie Wang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Weiding Wu, Chen Liu
Publikováno v:
World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-8 (2021)
Abstract Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC). Theref
Externí odkaz:
https://doaj.org/article/97b2d54f28c84ea58371efd07c86e3b6
Autor:
Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Chen Liu
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2020)
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy. Using next-generation sequencing (NGS),
Externí odkaz:
https://doaj.org/article/5010a92b482e48ba911dd2d523f4cf37
Autor:
Yunzhen Qian, Yitao Gong, Yu Liu, Yusheng Chen, Ruijie Wang, Zhengjie Dai, Xuan Zou, Yesiboli Tasiheng, Guopei Luo, Xuan Lin, Xu Wang, He Cheng, Xianjun Yu, Chen Liu
Publikováno v:
Journal of Immunology Research, Vol 2022 (2022)
Background. Pancreatic ductal adenocarcinoma (PDAC) displays a typical mucin expression pattern which is characterized by MUC1 positive, MUC2 negative, and MUC5AC positive. More and more evidences show that mucins are involved in the development of p
Externí odkaz:
https://doaj.org/article/ad65d435eeb7480d873e7b5138c41195
Autor:
Chen Liu MD, PhD, He Cheng MD, Kaizhou Jin MD, PhD, Zhiyao Fan MD, Yitao Gong MD, Yunzhen Qian MD, Shengming Deng MD, Qiuyi Huang MD, Quanxing Ni MD, Xianjun Yu MD, PhD, Guopei Luo MD, PhD
Publikováno v:
Cancer Control, Vol 27 (2020)
Lymphatic metastasis is a major determinant of the outcome of resected pancreatic cancer. Gemcitabine-based adjuvant chemotherapy can improve the outcome of resected pancreatic cancer. However, the efficacy of gemcitabine against pancreatic cancer st
Externí odkaz:
https://doaj.org/article/f000c65ebf8241d8bdbd31f43f6f96bc
Autor:
Yusheng Chen, Xuan Lin, Xuan Zou, Yunzhen Qian, Yu Liu, Ruijie Wang, Xu Wang, Xianjun Yu, Chen Liu, He Cheng
Background Pancreatic adenocarcinoma (PAAD) remains a lethal malignancy making the detection of novel prognostic biomarkers urgent. Limited studies have investigated the predictive capability of immune checkpoints in PAAD. Method Gene expression data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a0cd9cb492b973736021e6f48267f0
https://doi.org/10.21203/rs.3.rs-1719611/v2
https://doi.org/10.21203/rs.3.rs-1719611/v2
Autor:
Chen Liu, Yitao Gong, He Cheng, Xianjun Yu, Zhiwen Xiao, Kaizhou Jin, Guopei Luo, Yunzhen Qian
Publikováno v:
World Journal of Surgery. 45:2185-2190
To evaluate the clinical value of preoperative markers in predicting occult metastases in resectable pancreatic body and tail cancer judged by a recent multidetector computed tomography (MDCT) scan of the abdomen. The data from a retrospective collec
Autor:
Chen Liu, Shengming Deng, He Cheng, Yitao Gong, Zhiyao Fan, Kaizhou Jin, Xianjun Yu, Guopei Luo, Qiuyi Huang, Yunzhen Qian, Quanxing Ni
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2020)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy. Using next-generation sequencing (NGS), these abe